Biocon Biologics launches Hulio biosimilar in US EP News Bureau Jul 4, 2023 HULIO is available at a list price (wholesale acquisition cost) of five per cent below the current Humira list price.…
CCI clears Edelweiss-Biocon Biologics deal PTI May 10, 2023 The deal has been cleared under the green channel route
Serum and Biocon Biologics sign agreement to restructure equity investment EP News Bureau Apr 25, 2023 As per the new terms, Serum would make an additional equity investment of $150 million through the conversion of the $150 million…
Biocon Biologics wins Bioprocessing Excellence in South Asia Award at ABEA 2023 EP News Bureau Mar 29, 2023 The annual Asia-Pacific Bioprocessing Excellence Awards organised by IMAPAC, recognise organisations who demonstrate exceptional…
Biocon Biologics appoints Shreehas Tambe as Managing Director and CEO EP News Bureau Dec 5, 2022 He will lead Biocon Biologics in realising its goal of being a global biosimilars leader
Biocon Biologics completely acquires Viatris’s global biosimilars business EP News Bureau Dec 2, 2022 Biocon Biologics will recognise the combined revenue and associated profits from the acquired collaboration biosimilars with…
Biocon Biologics outlicenses two biosimilar assets to Yoshindo for commercialisation in Japan EP News Bureau Oct 17, 2022 bUstekinumab and bDenosumab to address market opportunity of approximately $700 million
Biocon Sdn Bhd enters Malaysia Book of Records EP News Bureau Aug 6, 2022 The 562,000 sq ft facility has been recognised as the first and largest integrated insulin manufacturer in Malaysia by MBR
India’s medicine watchdog under the scanner once again Viveka Roychowdhury Jun 30, 2022 Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Biocon Biologics denies bribery allegations EP News Bureau Jun 22, 2022 A statement from the company claimed that besides its employees, all its consultants, suppliers and partners are also bound by a…